… for both stroke and bleeding in patients with atrial fibrillation (AF).1 Oral anticoagulation
is associated with a net clinical benefit in elderly patients despite their elevated bleeding risk,2 …

… oral anticoagulants (OACs), such as vitamin K antagonists, but non–vitamin K antagonist oral
anticoagulants (… or guidelines for AF treatment in cancer patients (10). Post hoc analyses of …

… Direct oral anticoagulants (DOACs) are progressively … of patients with atrial fibrillation (AF),
with higher quality of life, … K antagonist oral anticoagulants in patients with atrial fibrillation …

… among patients with … oral anticoagulants (DOACs) have become available in the US market
providing alternative options to warfarin for anticoagulation therapy among NVAF patients. …

… To evaluate inter- and intra-individual variability in real-world atrial fibrillation patients on
dabigatran, rivaroxaban or apixaban in four Italian anticoagulation clinics and to assess the …

… This meta-analysis is the first to include data for all four new oral anticoagulants studied in …
embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk…

… recommend oral anticoagulant therapy for most patients with nonvalvular atrial fibrillation
with … is acceptable, the use of the drug is challenging for patients and physicians. The 3 novel …

… >50 000 patients. We found that the novel oral anticoagulants significantly reduced overall
… The novel oral anticoagulants may potentially address some of the limitations of vitamin K …

Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …

… Guidelines for the treatment of nonvalvular atrial fibrillation (AF) recommend oral anticoagulation
(OAC) for stroke prevention with either warfarin or direct oral anticoagulants (DOACs), …